Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Abstract

ObjectivesTo evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China.MethodsIn this phase 3, open-label extension period, eligible completers of study BEL113750 (NCT01345253)...